Michael Krathen

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

Youn H. Kim, Mahkam Tavallaee, Uma Sundram et al. · Journal of Clinical Oncology · 2015 · 281 citations · Full text

Medicine, Hematology, Oncology +17

A Comparison of the Malignancy Incidence Among Patients With Psoriatic Arthritis and Patients With Rheumatoid Arthritis in a Large US Cohort

Rachael L. Gross, Julie Schwartzman-Morris, Michael Krathen et al. · Arthritis & Rheumatology · 2014 · 69 citations

Medicine, Clinical Sciences, Internal Medicine +16

Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: Histologic and circulating leukocyte profile and potential risk of a systemic lupus flare

Inbal Braunstein, Noah Goodman, Misha Rosenbach et al. · Journal of the American Academy of Dermatology · 2011 · 65 citations

Life Sciences, Immunology, Pharmacotherapy +12

The cutaneous lupus erythematosus disease activity and severity index: Expansion for rheumatology and dermatology

Michael Krathen, Jonathan Dunham, Elizabeth Gaines et al. · Arthritis Care & Research · 2008 · 62 citations · Full text

Medicine, Dermatology, Dermatopathology +14

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression

Michael Krathen, Uma Sundram, Sameer Bashey et al. · Blood · 2012 · 24 citations

Life Sciences, Immunology, Oncology +5